Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Medacta Group SA ( (CH:MOVE) ) has provided an update.
Medacta Group SA, a Swiss orthopaedics manufacturer listed on SIX under the ticker MOVE, develops implants and surgical technologies for hip, knee, spine and extremities procedures, with a strong emphasis on minimally invasive techniques and personalized, technology-enabled solutions. The company continues to expand its global footprint, workforce and manufacturing base, including a new automated warehouse in Italy and its first non-Swiss production site in Florida.
Medacta reported record 2025 results with revenue rising 18.5% in constant currency to €683.8 million and adjusted EBITDA up 19.1% to €190.8 million, lifting the margin to 29.0% in constant currency. Growth was broad-based across all regions and product lines, highlighted by strong gains in knee and extremities and supported by innovations such as Kinematic Alignment platforms and NextAR augmented reality systems, while the Parcus Medical acquisition and capacity expansions in Italy and Switzerland underpin upgraded 2026 and mid-term growth guidance and a sharply higher dividend proposal.
The group generated a 31.0% increase in net profit to €95.5 million, a 42.5% rise in operating cash flow, and strengthened its balance sheet with higher equity and an improved equity ratio, while adding 258 employees to reach a total of 2,165 staff. By investing in supply chain optimization, vertical integration in sports medicine and ongoing production expansion, Medacta aims to sustain above-market growth and further enhance profitability, reinforcing its competitive position in the global orthopaedics market.
The most recent analyst rating on (CH:MOVE) stock is a Buy with a CHF185.00 price target. To see the full list of analyst forecasts on Medacta Group SA stock, see the CH:MOVE Stock Forecast page.
More about Medacta Group SA
Medacta Group SA is a Swiss medical device company specializing in orthopaedic solutions, including hip, knee, spine and extremities implants, as well as sports medicine and arthroscopy products. The group focuses on minimally invasive and personalized surgical techniques, supported by augmented reality and patient-specific planning tools, and serves hospitals and surgeons globally across EMEA, North America, Asia-Pacific and Latin America.
Average Trading Volume: 16,112
Technical Sentiment Signal: Buy
Current Market Cap: CHF3.06B
Find detailed analytics on MOVE stock on TipRanks’ Stock Analysis page.